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Patients Undergoing an Early Invasive
Strategy After Fibrinolysis for ST-Segment
Elevation Myocardial Infarction
A Patient-Level Analysis of the Randomized Early
Routine Invasive Clinical TrialsMina Madan, MD,* Sigrun Halvorsen, MD,y Carlo Di Mario, MD,z Mary Tan, MSC,x Cynthia M. Westerhout, PHD,k
Warren J. Cantor, MD,{ Michel R. Le May, MD,# Francesco Borgia, MD,** Federico Piscione, MD,yy
Bruno Scheller, MD,zz Paul W. Armstrong, MD,k Francisco Fernandez-Aviles, MD,xx Pedro L. Sanchez, MD,xx
John J. Graham, MD,kk Andrew T. Yan, MD,kk Shaun G. Goodman, MDxkkABSTRACTOBJECTIVES This study investigated the relationship between time to invasive assessment and outcomes among
ST-segment elevation myocardial infarction patients randomized to early angiography after ﬁbrinolysis.
BACKGROUND The optimal timing of coronary angiography after ﬁbrinolysis and the association with clinical outcomes
is uncertain.
METHODS Patient-level data from 6 randomized trials, with a median time to angiography <12 h after ﬁbrinolysis, were
pooled. The primary endpoint was 30-day death or reinfarction. The key secondary endpoint was in-hospital major
bleeding. The relationship between ﬁbrinolysis to angiography time and symptom onset to angiography time with
outcomes was studied using 2- and 4-h intervals, respectively, and in multivariable models.
RESULTS Among 1,238 patients, the median ﬁbrinolysis to angiography time was 165 min, and the median symptom
onset to angiography time was 5.33 h. The primary and key secondary endpoints occurred in 5.7% and 4.7%, respectively.
These main endpoints did not vary signiﬁcantly with increasing ﬁbrinolysis to angiography time. Early angiography (<2 h)
after ﬁbrinolysis was not associated with increased bleeding. Recurrent ischemia increased with increasing ﬁbrinolysis to
angiography time (3.7% to 7.9%, p for trend ¼ 0.02). Thirty-day and 1-year death/reinfarction and 30-day recurrent
ischemia increased signiﬁcantly with increasing symptom onset to angiography time. Neither ﬁbrinolysis to angiography
time nor symptom onset to angiography time was an independent predictor of the primary endpoint. Only symptom
onset to angiography time was an independent predictor of 1-year death/reinfarction (hazard ratio: 1.07, 95% conﬁdence
interval: 1.02 to 1.12, p ¼ 0.01).
CONCLUSIONS Very early angiography (<2 h) after ﬁbrinolysis was not associated with an increased risk of 30-day
death/reinfarction or in-hospital major bleeding, and angiography within 4 h after ﬁbrinolysis was associated with
reduced 30-day recurrent ischemia. A shorter symptom onset to angiography time (<4 h) was associated with reduced
30-day and 1-year death/reinfarction and 30-day recurrent ischemia. In the current environment of regional networks of
24/7 primary percutaneous coronary intervention (PCI) centers, the clinical implication of these ﬁndings is that patients
initially treated with ﬁbrinolysis should also be promptly transferred to the nearest PCI center for immediate angiography
and PCI. (Early Percutaneous Coronary Intervention [PCI] After Fibrinolysis Versus Standard Therapy in ST Segment
Elevation Myocardial Infarction [STEMI] Patients; NCT01014182) (J Am Coll Cardiol Intv 2015;8:166–74) © 2015 by the
American College of Cardiology Foundation.
AB BR E V I A T I O N S
AND ACRONYM S
GPI = glycoprotein IIb/IIIa
inhibitor
MI = myocardial infarction
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
ardial Infarction
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167I n ST-segment elevation myocardial infarction(STEMI), early routine percutaneous coronaryintervention (PCI) after ﬁbrinolysis results in a
reduction in the incidence of reinfarction, recur-
rent ischemia, and death or reinfarction (1–8). This
early invasive strategy achieves these beneﬁts
without an increase in the incidence of stroke or
major bleeding complications, and these beneﬁts
have been sustained in long-term follow-up (1–8).
Recent updates to the American College of Cardiol-
ogy, American Heart Association, and European Soci-
ety of Cardiology STEMI guidelines reﬂect these
ﬁndings (9,10).SEE PAGE 175Fibrinolysis followed by the early invasive strategy
is the treatment of choice for STEMI patients arriving
at hospitals unable to offer timely primary PCI.
However, the optimal timing of coronary angiog-
raphy after ﬁbrinolysis and its relationship with
clinical outcome is uncertain. In our previous cumu-
lative meta-analysis (8), data on optimal timing of
coronary angiography after ﬁbrinolysis or on selected
subgroups were not used. Thus, a patient-level
analysis of these trials was planned to explore
further the relationship between time to early angi-
ography and clinical outcomes among STEMI patients
randomized to a routine early invasive strategy after
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Patient-level data from 7 randomized trials
evaluating early invasive versus standard
management were included in a collaborative
patient-pooled database: CAPITAL AMI
(Combined Angioplasty and Pharmacological
Intervention Versus Thrombolysis Alone in
Acute Myocardial Infarction) study (N ¼ 170)
(1), SIAM III (Southwest German Interven-
tional Study in Acute Myocardial Infarction)
(N ¼ 197) (2), WEST (Which Early ST-Elevation
Myocardial Infarction Therapy) study (N ¼ 221) (3),
NORDISTEMI (NORwegian study on DIstrict treat-
ment of ST-Elevation Myocardial Infarction) (N ¼ 266)
(4), GRACIA-1 (Grupo de Análisis de la Cardiopatía
Isquémica Aguda-1) (N ¼ 500) (5), CARESS-in-AMI
(Combined Abciximab Reteplase Stent Study in
Acute Myocardial Infarction) study (N ¼ 597) (6), and
the TRANSFER-AMI (Trial of Routine Angioplasty
and Stenting after Fibrinolysis to Enhance Reperfu-
sion in Acute Myocardial Infarction) (N ¼ 1,059) (7).
STUDY POPULATION. The study population was the
early invasive cohort from the above-mentioned
studies (i.e., STEMI patients undergoing ﬁbrinolysis
and randomized to early angiography). Furthermore,
the patients included in this analysis were those
STEMI patients from trials in which the median
time from ﬁbrinolysis to angiography was <12 h. The
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168GRACIA-1 study was not included in the present
analysis because the invasive approach was under-
taken up to 24 h post-ﬁbrinolysis (median time from
ﬁbrinolysis to angiography of 17 h) (5).
DEFINITIONS. Door to needle time was deﬁned as the
time from hospital arrival to the administration of
ﬁbrinolysis (minutes). The ﬁbrinolysis to angiography
time was deﬁned as the time from ﬁbrinolysis
administration to coronary angiography (minutes).
Symptom onset to angiography time was deﬁned as
the time from symptom onset to angiography (hours).
The primary endpoint for this analysis was the 30-day
incidence of death or reinfarction. Key secondary
endpoints were the 30-day incidences of death,
reinfarction, recurrent ischemia, stroke, in-hospital
Thrombolysis In Myocardial Infarction (TIMI) major
bleeding, and the 1-year incidence of death, rein-
farction, and the combined incidence of death or
reinfarction.
STATISTICAL ANALYSIS. Categorical variables are
presented as frequency (percentage) of nonmissing
cases, whereas continuous variables are described as
median with interquartile range. Differences between
groups were compared using the Pearson chi-square,
Cochran-Armitage trend, and Kruskal-Wallis tests as
appropriate. Clinical outcomes were studied for the
overall study cohort as well as according to time from
ﬁbrinolysis to angiography (2-h intervals) and time
from symptom onset to angiography (4-h intervals).
The analysis of outcomes over time intervals was
exploratory in nature, and the time intervals were
chosen based on what may be considered clinically
relevant.
Multivariable models using Cox proportional
hazards regression and stratiﬁed by trial were used to
assess the relationship of ﬁbrinolysis to angiography
time and symptom onset to angiography time, as
continuous variables, with 30-day and 1-year death or
reinfarction. Baseline patient characteristics consid-
ered in the adjustment included age, sex, weight,
heart rate, systolic blood pressure, Killip class,
current smoker, history of hypertension, diabetes,
previous MI, and infarct location (11,12). Linearity and
proportional hazard assumptions were veriﬁed
graphically by checking the log-log survival curves
and residual plots. Approximately 8% of presenting
heart rate and systolic blood pressure values were
missing in the study population. Assuming data were
missing at random, we used multiple imputation to
impute the missing data. A single Markov chain
Monte Carlo method, which assumes multivariate
normality, was used. Results of the full models were
obtained after combining 5 complete datasets togenerate the inferences. The WEST study did not
collect data regarding the incidence of reinfarction at
1 year and was therefore not included in the model
created to study 1-year death or reinfarction. We
tested for interstudy heterogeneity, and no signiﬁ-
cant heterogeneity was found. All statistical com-
parisons were 2 tailed with statistical signiﬁcance
deﬁned at a p value <0.05. Analyses were performed
using SAS version 9.2 (SAS Institute Inc., Cary, North
Carolina).
RESULTS
BASELINE CHARACTERISTICS AND PROCEDURAL
VARIABLES. In the 6 clinical trials, there were
1,261 patients randomized to an early invasive
strategy. Of these patients, 20 did not undergo angi-
ography (6 patients experienced early death), and
3 patients were outliers (1 patient without the time or
date of thrombolysis recorded, and 2 patients with
the time to angiography >65 h), leaving 1,238 patients
in this analysis. There were 1 and 14 patients lost to
follow-up at 30 days and 1 year, respectively.
The median age was 59 years, and most patients
were Killip class I at presentation (Table 1, Online
Tables 1 and 2). The prevalence of previous MI or
previous revascularization procedures was low. The
median door to needle time was 35 min, and the
median time from ﬁbrinolysis to angiography was 165
min (range, 21 to 2,850 min). The median symptom
onset to angiography time was 5.3 h. Of 1,238 patients
undergoing angiography, 87% underwent PCI
(Table 2, Online Tables 3 and 4). The majority of pa-
tients undergoing angiography had a femoral vascular
access site. Coronary stenting was performed in
84.3% of patients, and the use of drug-eluting stents
was low (14.8%). The incidence of initial TIMI grade 3
ﬂow after ﬁbrinolysis was 55.4%. After PCI, 90.8%
achieved TIMI ﬂow grade 3. Glycoprotein IIb/IIIa in-
hibitors (GPIs) were used in 63.2% of cases and thie-
nopyridine therapy, with either clopidogrel or
ticlopidine, in 92.5% of cases.
CLINICAL OUTCOMES. The primary endpoint of
30-day death or reinfarction occurred in 5.7% of
patients, and the incidence of in-hospital TIMI major
bleeding was 4.7% (Table 3). When the patients were
divided into groups according to the time from ﬁbri-
nolysis to angiography (0 to 2 h, 2.1 to 4 h, >4 h), the
outcomes appeared similar across time intervals
except for recurrent ischemia, which increased
signiﬁcantly with time to angiography beyond 4 h
(p [trend] ¼ 0.02) (Table 3).
The relationship between symptom onset to angi-
ography time (4-h time intervals) is shown in Table 4.
TABLE 2 Procedural Characteristics (N ¼ 1,238)
PCI performed 1,080 (87.2)
Access site (if PCI performed)
Femoral 806/991 (81.3)
Radial 185/991 (18.7)
Infarct-related artery
Left main 6 (0.5)
Left circumﬂex 121 (9.8)
Left anterior descending 592 (47.8)
Right coronary artery 478 (38.6)
Unknown/none 41 (3.3)
Stent use 911/1,080 (84.3)
Bare metal 658/911 (72.2)
Drug eluting 135/911 (14.8)
Baseline TIMI ﬂow
0/1 305/1,205 (25.3)
2 232/1,205 (19.3)
3 668/1,205 (55.4)
Final TIMI ﬂow grade
0/1 37/1,087 (3.4)
2 63/1,087 (5.8)
3 987/1,087 (90.8)
Medications during hospitalization
GPIs 776/1,227 (63.2)
Heparin or low molecular weight heparin use 1,231 (99.4)
Aspirin 1,149/1,229 (93.5)
Clopidogrel/ticlopidine 1,137/1,229 (92.5)
Medications at discharge
Aspirin 1,013/1,113 (91.0)
Clopidogrel/ticlopidine 985/1,113 (88.5)
Beta-blocker 989/1,113 (88.9)
ACE/ARB inhibitor 895/1,113 (80.4)
Statin 1,017/1,113 (91.4)
Values are n (%) or n/N (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
GPIs ¼ glycoprotein IIb/IIIa inhibitors; PCI ¼ percutaneous coronary intervention;
TIMI ¼ Thrombolysis In Myocardial Infarction.
TABLE 1 Baseline Characteristics (N ¼ 1,238)
Age, yrs 59 (51–68)
Male 980 (79.2)
Hypertension 460/1,217 (37.8)
Diabetes 180/1,230 (14.6)
Dyslipidemia 307/995 (30.9)
Current or former smoker 780/1,229 (63.5)
Current smoker 610/1,229 (49.6)
Previous myocardial infarction 125/1,227 (10.2)
Previous angioplasty 67/1,237 (5.4)
Previous coronary bypass surgery 7/1,130 (0.6)
Weight, kg 80 (70–90) [n ¼ 1,217]
Systolic blood pressure, mm Hg 140 (125–160) [n ¼ 1,144]
Diastolic blood pressure, mm Hg 82 (73–93) [n ¼ 1,144]
Heart rate, beats/min 72 (61–85) [n ¼ 1,144]
Killip class
I 999/1,223 (81.7)
II 195/1,223 (15.9)
III 18/1,223 (1.5)
IV 11/1,223 (0.9)
Infarct location
Anterior 609/1,236 (49.3)
Inferior 591/1,236 (47.8)
Others 36/1,236 (2.9)
Fibrinolysis
Tenecteplase 855/1,238 (69.1)
Reteplase 380/1,238 (30.7)
Other 3/1,238 (0.2)
Time from symptom onset to
administration of ﬁbrinolysis, min
130 (83–202)
Door to needle time, min 35 (21–55) [n ¼ 949]
Fibrinolysis to angiography time, min 165 (115–228)
Symptom onset to angiography time, h 5.33 (3.95–7.37)
Values are median (interquartile range), n (%), or n/N (%).
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169The 30-day combined incidence of death or reinfarc-
tion increased from 4.0% to 8.0% with increasing
symptom onset to angiography time (p [trend] ¼
0.04). The incidence of recurrent ischemia increased
from 3.4% to 8.8% with increasing symptom onset to
angiography time (p [trend] ¼ 0.004). In-hospital
TIMI major bleeding was not signiﬁcantly affected
by increasing time from ﬁbrinolysis to angiography or
symptom onset to angiography time (p > 0.05 for
both parameters). Patients having the shortest time
interval from ﬁbrinolysis to angiography (0 to 2 h) did
not experience an increase in TIMI major bleeding
events during their hospitalization.
Patients having initial TIMI ﬂow grade 3 in the
culprit vessel at angiography had lower rates of 30
day and 1-year death or reinfarction compared with
patients having initial TIMI ﬂow grade 0 to 2 in the
culprit vessel (30-day: 3.6% vs. 8.4%, p ¼ 0.0004;
1-year: 6.1% vs. 11.3%, p ¼ 0.002).
After adjusting for other characteristics, neither
time from ﬁbrinolysis to angiography nor symptomonset to angiography time was a signiﬁcant inde-
pendent predictor of 30-day death or reinfarction
(Table 5, Figures 1 and 2). At 1-year follow-up, symp-
tom onset to angiography time was a signiﬁcant
independent predictor of death or reinfarction. For
every hour increase in symptom onset to angiog-
raphy time, there was a 7% relative increase in the
hazard of death or reinfarction within 1 year. To
evaluate whether the frequent use of GPIs in our
study cohort (63% of patients) explained the low
incidence of events, particularly at early time points
(0 to 2 h and 2.1 to 4 h), we introduced the use of
GPIs as a covariate in the multivariable models for
30-day death or reinfarction. The use of GPIs was not
a signiﬁcant predictor of 30-day death or reinfarction
in the model including time from ﬁbrinolysis to
angiography (p ¼ 0.42) nor in the model containing
symptom onset to angiography time (p ¼ 0.31); the
TABLE 3 Clinical Outcomes According to Time From Fibrinolysis to Angiography
Overall
(N ¼ 1,238)
0–2 h
(n ¼ 349)
2.1–4 h
(n ¼ 622)
>4 h
(n ¼ 267) p Value*
In-hospital
TIMI major bleeding 58 (4.7) 16 (4.6) 32 (5.1) 10 (3.8) 0.68
30 days†
Death or ReMI 70 (5.7) 17 (4.9) 36 (5.8) 17 (6.4) 0.41
Death 36 (2.9) 9 (2.6) 20 (3.2) 7 (2.6) 0.92
ReMI 37 (3.0) 8 (2.3) 18 (2.9) 11 (4.1) 0.19
Recurrent ischemia 57 (4.6) 13 (3.7) 23 (3.7) 21 (7.9) 0.02
Stroke 12 (1.0) 3 (0.9) 6 (1.0) 3 (1.1) 0.74
1 yr†
Death or ReMI‡ 93/1,117 (8.3) 25/341 (7.3) 55/574 (9.6) 13/202 (6.4) 0.95
Death 56/1,224 (4.6) 14/349 (4.0) 34/614 (5.5) 8/261 (3.1) 0.70
ReMI‡ 42/1,116 (3.8) 11/341 (3.2) 24/574 (4.2) 7/201 (3.5) 0.77
Values are n (%) or n/N (%). *p value for trend. †Lost to follow-up: 1 patient at 30 days and 14 patients at 1 year.
‡WEST (Which Early ST-Elevation Myocardial Infarction Therapy) study not included for 1-year death/reinfarction
or reinfarction.
ReMI ¼ reinfarction; TIMI ¼ Thrombolysis In Myocardial Infarction.
TABLE 4 Clinical Ou
In-hospital
TIMI major bleeding
30 days†
Death or ReMI
Death
ReMI
Recurrent ischemia
Stroke
1 yr†
Death or ReMI‡
Death
ReMI‡
Values are n (%) or n/N (%
‡WEST study not included
Abbreviations as in Tabl
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170interaction terms for the use of GPIs with these time
variables were also not signiﬁcant (p ¼ 0.67 and p ¼
0.92, respectively).
DISCUSSION
The question of optimal timing for invasive assess-
ment after ﬁbrinolysis in STEMI patients managed
using the pharmacoinvasive approach is highly rele-
vant to clinicians and interventional cardiologists at
receiving PCI centers. The present study uses the
largest available pooled clinical trial database using
individual patient-level data to address this ques-
tion. The main ﬁndings of this analysis were thattcomes According to Symptom Onset to Angiography Time
Overall
(N ¼ 1,238)
0–4 h
(n ¼ 328)
4.1–8 h
(n ¼ 661)
>8 h
(n ¼ 249) p Value*
58 (4.7) 14 (4.3) 31 (4.7) 13 (5.2) 0.59
70 (5.7) 13 (4.0) 37 (5.6) 20 (8.0) 0.04
36 (2.9) 6 (1.8) 20 (3.0) 10 (4.0) 0.12
37 (3.0) 7 (2.1) 19 (2.9) 11 (4.4) 0.12
57 (4.6) 11 (3.4) 24 (3.6) 22 (8.8) 0.004
12 (1.0) 2 (0.6) 5 (0.8) 5 (2.0) 0.11
93/1,117 (8.3) 22/312 (7.1) 46/614 (7.5) 25/191 (13.1) 0.03
56/1,224 (4.6) 11/326 (3.4) 30/653 (4.6) 15/245 (6.1) 0.12
42/1,116 (3.8) 11/312 (3.5) 19/614 (3.1) 12/190 (6.3) 0.18
). *p value for trend. †Lost to follow-up: 1 patient at 30 days and 14 patients at 1 year.
for 1-year death/reinfarction or reinfarction.
e 3.time from ﬁbrinolysis to angiography was not inde-
pendently predictive of 30-day or 1-year death
or reinfarction among ﬁbrinolysis-treated STEMI
patients undergoing early angiography. The time
from symptom onset to angiography, however, was
a signiﬁcant predictor of 1-year death or reinfarc-
tion. Very early angiography (<2 h) after ﬁbrinolysis
and a shorter symptom onset to angiography time
(<4 h) was not associated with an increased risk of
30-day death or reinfarction or in-hospital major
bleeding. Early angiography (<4 h after ﬁbrinolysis)
was associated with a lower frequency of recurrent
ischemia.
Time from ﬁbrinolysis to angiography is inﬂuenced
by clinical factors (hemodynamic stability, reperfu-
sion status after ﬁbrinolysis, risk of bleeding), trans-
portation factors (ability to arrange timely transfer to
receiving institution), and factors at the receiving
institution (ability to assemble an interventional
team in a timely manner). The time from symptom
onset to angiography includes time to angiography
after contact with the medical system, but is also
heavily dependent on the patient’s decision to seek
medical attention for his or her symptoms, and the
manner of transportation to the initial institution
(self-transportation vs. ambulance call). Because this
analysis did not deﬁnitively identify a direct rela-
tionship between time from ﬁbrinolysis to angiog-
raphy and the incidence of 30-day or 1-year death
or reinfarction, one could question the merits of the
early invasive strategy in this population and
consider deferral of angiography to the following day
for the stabilized STEMI patient arriving outside
working hours. However, we did ﬁnd indirect evi-
dence of the importance of early invasive treatment
on late outcomes based on the signiﬁcant relationship
of symptom onset to angiography time with the
combined incidence of death or reinfarction at 1 year.
Furthermore, when we compared the incidence of
30-day and 1-year death or reinfarction in our study
cohort with the conservatively managed cohort of the
pooled database, the pharmacoinvasive approach
remained a dominant strategy over conservatively
managed patients (30-day death/reinfarction, 11.8%
vs. 5.7%, p < 0.001 and 1-year death/reinfarction,
13.6% vs. 8.3%, p ¼ 0.0005).
Dimopoulos et al. (13) demonstrated in the
CARESS-in-AMI trial that a mortality beneﬁt was
realized if revascularization took place within 3.35 h
after hospitalization and ﬁbrinolysis. This was likely
achieved due to a reduction in the time to reperfusion
among those patients with failed ﬁbrinolysis (13).
Furthermore, Danchin et al. (14) demonstrated that
when used early after the onset of symptoms
FIGURE 1 Association Between Time to Invasive Assessment and Clinical Outcomes
Adjusted associations between time from ﬁbrinolysis to angiography and time from
symptom onset to angiography with 30-day and 1-year outcomes. The hazard ratios are
per hour of delay to angiography.
TABLE 5 Clinical Predictors of Death or Reinfarction*
Variable HR 95% CI p Value
Time from ﬁbrinolysis to angiography model: 30 days
Age per 1-yr increase 1.07 (1.05–1.10) <0.0001
Presenting heart rate (per 1-U increase) 1.03 (1.02–1.04) <0.0001
Killip class $II 2.22 (1.24–3.97) 0.0072
Fibrinolysis to angiography time* 1.01 (0.95–1.08) 0.78
Time from symptom onset to angiography model: 30 days
Age (per 1-yr increase) 1.07 (1.05–1.10) <0.0001
Presenting heart rate (per 1-U increase) 1.03 (1.02–1.04) <0.0001
Killip class $II 2.20 (1.24–3.93) 0.0074
Systolic blood pressure >140 mm Hg 0.59 (0.33–1.04) 0.068
Symptom onset to angiography time* 1.03 (0.98–1.08) 0.30
Time from ﬁbrinolysis to angiography model: 1 yr
Age (per 1-yr increase) 1.07 (1.05–1.10) <0.0001
Presenting heart rate (per 1-U increase) 1.03 (1.02–1.04) <0.0001
Killip class $II 1.75 (1.07–2.84) 0.025
Systolic blood pressure >140 mm Hg 0.42 (0.25–0.69) 0.0007
Diabetes 1.84 (1.11–2.93) 0.017
Fibrinolysis to angiography time* 1.04 (0.96–1.13) 0.32
Time from symptom onset to angiography model: 1 yr
Age per 1-yr increase 1.07 (1.04–1.09) <0.0001
Presenting heart rate per 1-U increase 1.03 (1.02–1.04) <0.0001
Killip class $II 1.79 (1.10–2.91) 0.018
Systolic blood pressure >140 mm Hg 0.40 (0.25–0.67) 0.0004
Diabetes 1.78 (1.10–2.87) 0.019
Symptom onset to angiography time* 1.07 (1.02–1.13) 0.0054
*Per 1-h increase in this variable.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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171(<220 min), a pharmacoinvasive strategy yielded
in-hospital, 30-day, and 1-year survival rates that
were comparable to those of primary PCI. Recently,
the STREAM (Strategic Reperfusion Early After
Myocardial Infarction) investigators demonstrated
comparable 30-day clinical outcomes when STEMI
patients within 3 h of symptom onset received pre-
hospital ﬁbrinolysis a median of 100 min after the
onset of symptoms was compared with primary PCI.
More intracranial hemorrhage was observed in the
ﬁbrinolysis group, however (15). In contrast to the
Danchin et al. study, we did not observe an increase
in mortality when time from ﬁbrinolysis to angiog-
raphy and PCI was <2 h. The difference may be
explained by the mandatory immediate transfer of all
patients according to trial design in our pooled anal-
ysis versus the clustering of rescue angioplasty in
patients with failed reperfusion in the Danchin et al.
study. Our analysis would suggest that seeking
medical attention as soon as possible, for a shorter
symptom onset to ﬁbrinolysis time (median of 130
min in our cohort) is an important driver of improved
clinical outcomes in the long term and perhaps rela-
tively more so than achieving a shorter time from
ﬁbrinolysis to angiography.
Although GPIs were used frequently in our study
cohort (63% of patients), GPI use was not a signiﬁcant
predictor of 30-day death or MI in our multivariable
models. Of the 6 pooled studies examined in our
analysis, 1 study (CARESS-in-AMI [6]) mandated the
use of half-dose reteplase and abciximab in all pa-
tients, whereas in the other trials, the use of GPIs was
discretionary and not randomized. It is difﬁcult to
know whether patients experiencing reinfarction
preferentially received GPIs because they were
having a recurrent event or it was simply operator
preference to use the agent routinely during STEMI
PCI (more likely). The use of GPIs is less frequent
nowadays; they have been replaced by potent anti-
platelet drugs such as ticagrelor and prasugrel, which
give GPI-like levels of platelet inhibition. Whether the
combination of ticagrelor or prasugrel with throm-
bolysis mitigates early events or poses an early haz-
ard is currently unknown.
Over the past 5 to 7 years, the predominant mode
of reperfusion therapy has shifted from ﬁbrinolysis to
primary PCI (16,17) with the development of regional
STEMI programs. For example, in the United
Kingdom, among revascularized STEMI patients, the
proportion of patients undergoing ﬁbrinolysis
decreased from 60% in 2008 to 6% in 2011, and the
incidence of primary PCI increased from 46% to 94%
over the same time period (p < 0.001) (18). Similar
trends have been observed in North America (19).Although primary PCI is the preferred reperfusion
strategy for STEMI patients, this approach is not
feasible for many patients residing in rural locations
with long transfer distances to PCI facilities (20). For
FIGURE 2 Kaplan-Meier Curve for 30-Day and 1-Year Death or Reinfarction
Kaplan-Meier curve for 30-day and 1-year death or reinfarction, according to time from ﬁbrinolysis to angiography (top) and symptom onset to
angiography time (bottom).
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172these patients, ﬁbrinolysis followed by the early
invasive approach has been incorporated as part of
most modern-day regional systems of STEMI care
(16,17,20).
Patients undergoing very early angiography (<2 h)
after ﬁbrinolysis had clinical outcomes comparable to
those of patients undergoing angiography at later
time points. Trials of facilitated primary PCI have
cautioned against performing PCI very early after
ﬁbrinolysis due to excess hazard observed among the
patients treated in this manner (21,22). The early
invasive approach evaluated in our trials should be
distinguished from a facilitated PCI strategy. Facili-
tated PCI was formally investigated in the large
ASSENT-4 PCI (Assessment of the Safety and Efﬁcacy
of a New Treatment Strategy With Percutaneous
Coronary Intervention-4), the FINESSE (Facilitated
Intervention With Enhanced Reperfusion Speed toStop Events) study, and several smaller studies
(21–23). In this strategy, ﬁbrinolysis was investigated
as a form of adjunctive therapy, along with aspirin
and anticoagulant therapy, before primary PCI. The
time interval between ﬁbrinolysis and balloon inﬂa-
tion was typically shorter than noted in early invasive
studies (median of 104 min in the ASSENT-4 PCI and
90 min in the FINESSE) (21,22). In these studies,
facilitation of primary PCI with ﬁbrinolysis was
associated with higher mortality, stroke, and bleeding
complications compared with primary PCI alone and
cannot be recommended as a viable STEMI strategy
(21–23). Because the facilitated PCI strategy differed
from the early invasive approach with respect to time
from ﬁbrinolysis to angiography, intent of primary
PCI, and use of adjunctive antiplatelet therapies,
such studies were not considered for inclusion in the
present analysis.
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173In addition to improved infarct-related artery
patency, and long-term survival, primary PCI results
in decreased neurological complications, and a
reduction in recurrent ischemia and reinfarction
compared with ﬁbrinolytic therapy (24). In our study,
we conﬁrmed the salutary effects of an early invasive
approach for those STEMI patients unable to access
primary PCI. The early invasive approach did not
result in excessive rates of bleeding or stroke despite
patients arriving at the cath lab a median of 165 min
(2 h and 45 min) after ﬁbrinolysis. In fact, even for
patients with a time from ﬁbrinolysis to angio-
graphy <2 h (n ¼ 349), major bleeding events were not
increased compared with patients having angiography
performed at later time points. Furthermore, we
conﬁrmed a reduction in recurrent ischemia for those
patients undergoing revascularization at earlier time
points. Patients undergoing revascularization early
likely had early infarct-related artery stabilization
without subsequent ischemic events.
STUDY LIMITATIONS. This was a retrospective anal-
ysis of a pooled patient database from 6 previous
randomized trials. These trials had varying deﬁni-
tions for certain variables, limiting our ability to
combine all variables across studies (e.g., deﬁnition
of recurrent ischemia, bleeding). The trials had vari-
able use of certain drugs (e.g., GPIs) and angiography
techniques (radial vs. femoral approach). Missing
data for certain variables and outcomes limited our
power to detect differences where they may exist. We
could not comment on the effects of pre-hospital
versus in-hospital ﬁbrinolysis using this dataset nor
did we examine the outcomes of patients undergoing
rescue PCI after failed thrombolysis. Furthermore, if
the dataset had been larger and with higher eventrates, we may have been able to demonstrate a rela-
tionship for time from ﬁbrinolysis to angiography and
outcomes in higher risk subgroups where time is
traditionally thought to be important in determining
outcomes, such as anterior MI or higher Killip class.
Finally, the comparison of clinical outcomes by time
intervals was nonrandomized, and we had limited
power to detect potential differences in outcomes
based on time trends. A post-hoc power calculation
for 30-day death or reinfarction revealed power of
only 3.3%, and 9.4% for in-hospital major bleeding,
respectively.
CONCLUSIONS
Very early angiography (<2 h) after ﬁbrinolysis was
not associated with an increased risk of 30-day death
or reinfarction or in-hospital major bleeding, and
angiography within 4 h after ﬁbrinolysis was asso-
ciated with a reduced rate of 30-day recurrent
ischemia. A shorter symptom onset to angiography
time (<4 h) was associated with reduced 30-day and
1-year death or reinfarction, and a reduction in 30-day
recurrent ischemia. In the current environment
characterized by the development of regional net-
works of 24/7 primary PCI centers, the clinical impli-
cation of these ﬁndings is that patients initially
treated with ﬁbrinolysis should also be promptly
transferred to the nearest PCI center for immediate
angiography and PCI.
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